At a glance
ClinicalIndex Comparison RecordN/ACompleted· 4,188 enrolled
Drug / intervention
Pantoprazoledrug
Likely dose
Pantoprazole 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pantoprazole 20/40 mg in Reflux-Associated Complaints With Focus on Gastrointestinal Symptoms
In Brief
An observational study evaluating Pantoprazole for Gastroesophageal Reflux Disease. Completed, enrolled 4,188 participants across 717 sites.
Detailed Summary
The aim of this study was to evaluate the effect of 14 days treatment with Pantoprazole 40 mg and 20 mg on gastroesophageal reflux disease (GERD) related symptoms in a large patient population.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedJan 2009
Primary CompletionApr 2009
Study CompletionJun 2009
TodayJul 2026
First PostedJan 27, 2009
Enrollment StartJan 1, 2009
Primary CompletionApr 1, 2009
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.4 years ago
Interventions
Pantoprazoledrug
This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).